04:32 PM EDT, 05/01/2025 (MT Newswires) -- Summit Therapeutics ( SMMT ) reported a Q1 non-GAAP net loss late Thursday of $0.07 per diluted share, compared with a loss of $0.05 a year earlier.

Three analysts polled by FactSet expected a GAAP loss of $0.09.

The biopharmaceutical company did not report any revenue. The company reported cash, cash equivalents and short-term investments of $361.3 million as of March 31, down from $412.3 million at 2024-end.